Precision medicine: What is so difficult? The interplay and complexities of pharmaceutical and diagnostic partnerships to deliver the promise of precision medicine

<h2>Abstract</h2><h3>Purpose</h3> Precision medicine (PM) holds the promise of transforming healthcare through tailored treatments for an individual's disease, improving outcomes and reducing adverse effects, by delivering the optimal treatment, at the right dose, at the right time. This study explores the intricate interplay between pharmaceutical companies and diagnostic partners, highlighting the substantial opportunity costs and risks involved due to inherent complexities and challenges with successful PM implementation. <h3>Methods</h3> A total of 19 diagnostic business leaders, representing 12 companies, participated in structured interviews. Four key topics were explored: (1) the healthcare continuum; (2) partnerships and collaborations with pharmaceutical companies; (3) market dynamics and competition; (4) economic and logistical barriers to diagnostics and PM. These executives provided their perspectives, which were subsequently delineated in more detail through additional analysis. <h3>Results</h3> Interviews highlighted systemic misalignments hindering PM adoption. Inadequate, variable, and lengthy time-to-reimbursement, unclear clinical evidence standards, regulatory uncertainty, along with policies that slow technological advancement were cited as key barriers. High attrition rates and small patient populations, coupled with expensive and high failure rates for clinical trials compounded these challenges, with the burden from the European Union (EU) <i>In-Vitro</i> Diagnostic Regulation (IVDR) further adding complexity. <h3>Conclusion</h3> Our study revealed economic and logistical obstacles that must be overcome to deliver effective PM for patients. By understanding these complexities, stakeholders can better navigate the path forward, fostering more effective partnerships and delivering innovative solutions to translate PM from attractive concept to clinical reality.